Myovant shares soar 27% on news of Pfizer prostate cancer drug collaboration worth up to $4.2 billion
Shares of Myovant Sciences soared 27% Monday, after its parent Sumitovant Biopharma unveiled an agreement with Pfizer Inc. to jointly develop a treatment for prostate cancer and women’s health in a deal worth up to $4.2 billion in upfront and potential milestone payments.
